News
PRPO
29.49
+3.47%
0.99
Weekly Report: what happened at PRPO last week (0406-0410)?
Weekly Report · 2d ago
Precipio COO Sabet Ahmed Zaki buys 19 common shares for $530.67
Reuters · 5d ago
Precipio Earnings Call Signals Profitable Growth Pivot
TipRanks · 04/09 00:12
Weekly Report: what happened at PRPO last week (0330-0403)?
Weekly Report · 04/06 09:57
Precipio GAAP EPS of -$0.23, revenue of $24.05M
Seeking Alpha · 04/06 07:36
Here are the major earnings after the close Thursday
Seeking Alpha · 04/02 14:00
Earnings Scheduled For April 2, 2026
Benzinga · 04/02 11:11
Precipio FY25 net sales climb 30% to $24M; operating loss narrows to $1.2M
Reuters · 03/30 21:41
Weekly Report: what happened at PRPO last week (0323-0327)?
Weekly Report · 03/30 09:58
Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more
Seeking Alpha · 03/29 12:07
Weekly Report: what happened at PRPO last week (0316-0320)?
Weekly Report · 03/23 09:54
Weekly Report: what happened at PRPO last week (0309-0313)?
Weekly Report · 03/16 09:54
Precipio Inc. to Host Q4 and Year-End 2025 Shareholder Update Call
Reuters · 03/12 21:00
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Barchart · 03/12 16:00
Precipio announces publication in Journal of Clinical Pathology
TipRanks · 03/10 13:05
Weekly Report: what happened at PRPO last week (0302-0306)?
Weekly Report · 03/09 09:55
Weekly Report: what happened at PRPO last week (0223-0227)?
Weekly Report · 03/02 09:54
Blood cancer diagnostics firm Precipio's prelim Q4 revenue rises 23% 
Reuters · 02/25 14:44
*Precipio 4Q Rev $6.7M >PRPO
Dow Jones · 02/25 14:38
*Precipio 4Q Net $500,000 >PRPO
Dow Jones · 02/25 14:38
More
Webull provides a variety of real-time PRPO stock news. You can receive the latest news about Precipio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.